Irreversible pulmonary hypertension after treatment with fenfluramine.
作者信息
McMurray J, Bloomfield P, Miller H C
出版信息
Br Med J (Clin Res Ed). 1986 Jan 25;292(6515):239-40. doi: 10.1136/bmj.292.6515.239-a.
Abstract
摘要
相似文献
1
Irreversible pulmonary hypertension after treatment with fenfluramine.
Br Med J (Clin Res Ed). 1986 Jan 25;292(6515):239-40. doi: 10.1136/bmj.292.6515.239-a.
2
Irreversible pulmonary hypertension after treatment with fenfluramine.
Br Med J (Clin Res Ed). 1986 Apr 26;292(6528):1137. doi: 10.1136/bmj.292.6528.1137.
3
Irreversible pulmonary hypertension after treatment with fenfluramine.
Br Med J (Clin Res Ed). 1986 Jul 5;293(6538):51-2. doi: 10.1136/bmj.293.6538.51-d.
4
Pulmonary hypertension and fenfluramine.
Eur Respir J. 1990 May;3(5):606-7.
5
Fenfluramine--induced irreversible pulmonary hypertension.
Postgrad Med J. 1991 Aug;67(790):776-7. doi: 10.1136/pgmj.67.790.776-a.
6
Pulmonary hypertension and fenfluramine.
Br Med J (Clin Res Ed). 1981 Oct 3;283(6296):881-3. doi: 10.1136/bmj.283.6296.881.
7
8
Pulmonary hypertension, hyperthyroidism, and fenfluramine: a case report and review.
MedGenMed. 2006 Nov 8;8(4):29.
9
[Pulmonary hypertension following use of fenfluramine for obesity].
Ned Tijdschr Geneeskd. 1994 Dec 10;138(50):2500-2.
10
Pulmonary hypertension and dexfenfluramine.
Eur J Clin Pharmacol. 1995;48(1):81-3. doi: 10.1007/BF00202179.
引用本文的文献
1
5-HT Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators.
Nutrients. 2023 Mar 17;15(6):1449. doi: 10.3390/nu15061449.
2
Potential of the TRPM7 channel as a novel therapeutic target for pulmonary arterial hypertension.
J Smooth Muscle Res. 2022;58(0):50-62. doi: 10.1540/jsmr.58.50.
3
Implications of immune-inflammatory responses in smooth muscle dysfunction and disease.
J Smooth Muscle Res. 2019;55(0):81-107. doi: 10.1540/jsmr.55.81.
4
The unrelenting fall of the pharmacological treatment of obesity.
Endocrine. 2013 Dec;44(3):598-609. doi: 10.1007/s12020-013-9983-1. Epub 2013 May 16.
5
Safety of drug therapies used for weight loss and treatment of obesity.
Drug Saf. 2006;29(4):277-302. doi: 10.2165/00002018-200629040-00001.
6
Respiratory toxicities from stimulant use.
Clin Rev Allergy Immunol. 1997 Fall;15(3):221-41. doi: 10.1007/BF02737699.
7
A dangerous duo? A combination of common diet drugs (fen-phen) may lead to heart valve disease.
CMAJ. 1997 Sep 15;157(6):705-6.
8
Appetite suppressants and primary pulmonary hypertension in the United Kingdom.
Br Heart J. 1995 Dec;74(6):660-3. doi: 10.1136/hrt.74.6.660.
9
Primary pulmonary hypertension and fenfluramine use.
Br Heart J. 1993 Dec;70(6):537-41. doi: 10.1136/hrt.70.6.537.
10
Dietary pulmonary hypertension.
Thorax. 1994;49 Suppl(Suppl):S33-8. doi: 10.1136/thx.49.suppl.s33.
本文引用的文献
1
[A case of chronic pulmonary hypertension after fenfluramine intake].
Wien Klin Wochenschr. 1982 Nov 26;94(22):618-22.
2
Pulmonary hypertension and fenfluramine.
Br Med J (Clin Res Ed). 1981 Oct 3;283(6296):881-3. doi: 10.1136/bmj.283.6296.881.
3
Primary pulmonary hypertension: natural history and the importance of thrombosis.
Circulation. 1984 Oct;70(4):580-7. doi: 10.1161/01.cir.70.4.580.
4
[Are the primary vascular forms of chronic pulmonary heart disease becoming more common?].
Schweiz Med Wochenschr. 1968 Oct 12;98(41):1579-89 contd.
5
Haemodynamic effects of oral aminorex and amphetamine in unanaesthetized beagle dogs.
Thorax. 1972 Jan;27(1):120-6. doi: 10.1136/thx.27.1.120.
Zotero 插件